Suppr超能文献

新型微管蛋白和 HDAC 双重靶向抑制剂的抗肿瘤活性评价。

Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.

机构信息

Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.

Department of Pharmacology, College of Basic Medicine, Qingdao University, Qingdao, Shandong, China.

出版信息

Bioorg Med Chem Lett. 2019 Sep 15;29(18):2638-2645. doi: 10.1016/j.bmcl.2019.07.045. Epub 2019 Jul 24.

Abstract

Histone deacetylases (HDACs) have proven to be promising targets for the development of anti-cancer drugs. In this study, we reported a series of novel chalcone based tubulin and HDAC dual-targeting inhibitors. Three compounds inhibited the activities of HDAC and tubulin polymerization simultaneously and displayed anti-proliferative activities toward eleven human tumor cell lines. Compound 8a remarkably induced growth inhibition, apoptosis and G2/M phase arrest of A549 tumor cells. Finally, the inhibitory activities of 8a against HDAC6 and tubulin were rationalized by molecular docking studies.

摘要

组蛋白去乙酰化酶(HDACs)已被证明是开发抗癌药物的有前途的靶点。在这项研究中,我们报道了一系列新型基于查尔酮的微管蛋白和 HDAC 双重靶向抑制剂。三种化合物同时抑制 HDAC 和微管蛋白聚合的活性,并对 11 种人肿瘤细胞系表现出抗增殖活性。化合物 8a 显著诱导 A549 肿瘤细胞的生长抑制、凋亡和 G2/M 期阻滞。最后,通过分子对接研究合理地解释了 8a 对 HDAC6 和微管蛋白的抑制活性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验